These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

447 related items for PubMed ID: 28978939

  • 21. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
    Jia M, Lu H, Markowitz M, Cheng-Mayer C, Wu X.
    J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
    [Abstract] [Full Text] [Related]

  • 22. Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses.
    Pollara J, Bonsignori M, Moody MA, Pazgier M, Haynes BF, Ferrari G.
    Curr HIV Res; 2013 Jul; 11(5):378-87. PubMed ID: 24191939
    [Abstract] [Full Text] [Related]

  • 23. The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.
    O'Connell RJ, Kim JH, Excler JL.
    Expert Rev Vaccines; 2014 Dec; 13(12):1489-500. PubMed ID: 25163695
    [Abstract] [Full Text] [Related]

  • 24. Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific Fc-Mediated Antibody Activities in Women.
    Fisher KL, Mabuka JM, Sivro A, Ngcapu S, Passmore JS, Osman F, Ndlovu B, Abdool Karim Q, Abdool Karim SS, Chung AW, Baxter C, Archary D.
    Front Immunol; 2020 Dec; 11():1274. PubMed ID: 32733445
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir.
    Mujib S, Liu J, Rahman AKMN, Schwartz JA, Bonner P, Yue FY, Ostrowski MA.
    J Virol; 2017 Aug 15; 91(16):. PubMed ID: 28592534
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.
    Zolla-Pazner S, deCamp A, Gilbert PB, Williams C, Yates NL, Williams WT, Howington R, Fong Y, Morris DE, Soderberg KA, Irene C, Reichman C, Pinter A, Parks R, Pitisuttithum P, Kaewkungwal J, Rerks-Ngarm S, Nitayaphan S, Andrews C, O'Connell RJ, Yang ZY, Nabel GJ, Kim JH, Michael NL, Montefiori DC, Liao HX, Haynes BF, Tomaras GD.
    PLoS One; 2014 Aug 15; 9(2):e87572. PubMed ID: 24504509
    [Abstract] [Full Text] [Related]

  • 30. Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.
    Wen Y, Trinh HV, Linton CE, Tani C, Norais N, Martinez-Guzman D, Ramesh P, Sun Y, Situ F, Karaca-Griffin S, Hamlin C, Onkar S, Tian S, Hilt S, Malyala P, Lodaya R, Li N, Otten G, Palladino G, Friedrich K, Aggarwal Y, LaBranche C, Duffy R, Shen X, Tomaras GD, Montefiori DC, Fulp W, Gottardo R, Burke B, Ulmer JB, Zolla-Pazner S, Liao HX, Haynes BF, Michael NL, Kim JH, Rao M, O'Connell RJ, Carfi A, Barnett SW.
    PLoS One; 2018 Aug 15; 13(4):e0194266. PubMed ID: 29698406
    [Abstract] [Full Text] [Related]

  • 31. Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV.
    Zolla-Pazner S, Alvarez R, Kong XP, Weiss S.
    Curr Opin HIV AIDS; 2019 Jul 15; 14(4):309-317. PubMed ID: 30994501
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
    Cohen YZ, Lorenzi JCC, Seaman MS, Nogueira L, Schoofs T, Krassnig L, Butler A, Millard K, Fitzsimons T, Daniell X, Dizon JP, Shimeliovich I, Montefiori DC, Caskey M, Nussenzweig MC.
    J Virol; 2018 Mar 01; 92(5):. PubMed ID: 29237833
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Polyfunctional Fc Dependent Activity of Antibodies to Native Trimeric Envelope in HIV Elite Controllers.
    Kant S, Zhang N, Barbé A, Routy JP, Tremblay C, Thomas R, Szabo J, Côté P, Trottier B, LeBlanc R, Rouleau D, Harris M, Dupuy FP, Bernard NF.
    Front Immunol; 2020 Mar 01; 11():583820. PubMed ID: 33101312
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
    Qiao Y, Man L, Qiu Z, Yang L, Sun Y, He Y.
    Antiviral Res; 2016 Aug 01; 132():252-61. PubMed ID: 27387828
    [Abstract] [Full Text] [Related]

  • 38. Uninfected Bystander Cells Impact the Measurement of HIV-Specific Antibody-Dependent Cellular Cytotoxicity Responses.
    Richard J, Prévost J, Baxter AE, von Bredow B, Ding S, Medjahed H, Delgado GG, Brassard N, Stürzel CM, Kirchhoff F, Hahn BH, Parsons MS, Kaufmann DE, Evans DT, Finzi A.
    mBio; 2018 Mar 20; 9(2):. PubMed ID: 29559570
    [Abstract] [Full Text] [Related]

  • 39. Comprehensive investigation of common antibody-dependent cell-mediated cytotoxicity antibody epitopes of HIV-1 CRF01_AE gp120.
    Ampol S, Pattanapanyasat K, Sutthent R, Permpikul P, Kantakamalakul W.
    AIDS Res Hum Retroviruses; 2012 Oct 20; 28(10):1250-8. PubMed ID: 22288892
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.